Dupilumab recommended for severe asthma with type 2 inflammation

2021 ◽  
Keyword(s):  
Severe Asthma ◽  
Type 2 Inflammation

scholarly journals COVID-19, severe asthma and biologicals targeting type 2 inflammation: results in a third-level hospital in Madrid, Spain.

2021 ◽  
Vol 147 (2) ◽  
pp. AB40
Author(s):  
Alicia Domínguez Estirado ◽  
Gabriela Zambrano Ibarra ◽  
Filip Skrabski ◽  
Francisco Javier De Castro Martínez ◽  
Julia De Pedro ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Level Hospital ◽  
Type 2 Inflammation

P068 DUPILUMAB REDUCES BIOMARKERS OF TYPE 2 INFLAMMATION IN CHILDREN WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA

2021 ◽  
Vol 127 (5) ◽  
pp. S33
Author(s):  
L. Bacharier ◽  
J. Maspero ◽  
C. Katelaris ◽  
A. Fiocchi ◽  
D. Liu ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Type 2 Inflammation

Biologics targeting type 2 inflammation in severe asthma

Severe Asthma ◽  
2019 ◽  
pp. 285-303 ◽  
Author(s):  
Ian D. Pavord ◽  
Rahul Shrimanker ◽  
Nicola A. Hanania
Keyword(s):  
Severe Asthma ◽  
Type 2 Inflammation

Therapeutic Targeting of Type 2 Inflammation for the Treatment of Severe Asthma

2014 ◽  
Vol 1 (1) ◽  
pp. 2-10
Author(s):  
Lawren Wu ◽  
Joseph Arron ◽  
Jeffrey Harris ◽  
John Matthews ◽  
Karin Rosen
Keyword(s):  
Severe Asthma ◽  
Therapeutic Targeting ◽  
Type 2 Inflammation

scholarly journals Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma

2020 ◽  
Vol 6 (1) ◽  
pp. 00204-2019 ◽  
Author(s):  
Mario Castro ◽  
Klaus F. Rabe ◽  
Jonathan Corren ◽  
Ian D. Pavord ◽  
Constance H. Katelaris ◽  
...  
Keyword(s):  
Lung Function ◽  
Severe Asthma ◽  
Human Monoclonal Antibody ◽  
Forced Expiratory Volume ◽  
Interleukin 4 ◽  
Blood Eosinophil ◽  
Elevated Type ◽  
Forced Expiratory Flow ◽  
Type 2 Inflammation

BackgroundDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 200 mg or 300 mg every 2 weeks reduced exacerbations and improved forced expiratory volume in 1 s (FEV1) and quality of life over 52 weeks. This analysis evaluates dupilimab's effect on lung function in the overall population, and subgroups with baseline elevated type 2 inflammatory biomarkers.MethodsPatients were randomised to 52 weeks of subcutaneous dupilumab 200 mg every 2 weeks, 300 mg every 2 weeks, or matched-volume placebos. Lung function outcomes were analysed in the overall population, in patients with ≥150 eosinophils·µL−1, ≥300 eosinophils·µL−1, ≥25 ppb fractional exhaled nitric oxide (FeNO), and both ≥150 eosinophils·µL−1 and ≥25 ppb FeNO, at baseline.ResultsDupilumab treatment (200 mg and 300 mg every 2 weeks) resulted in significant improvements versus placebo after 52 weeks in pre-bronchodilator FEV1 (0.20 and 0.13 L, respectively, versus placebo) and post-bronchodilator FEV1 (0.19 and 0.13 L, respectively), forced vital capacity (FVC) (0.20 and 0.14 L, respectively), forced expiratory flow (0.19 and 0.13 L·s−1, respectively) and pre-bronchodilator FEV1/FVC ratio (1.75% and 1.61%, respectively) in the overall population (p<0.001). Difference versus placebo in post-bronchodilator FEV1 slope of change (weeks 4–52) was significant (0.04 L·year−1; p<0.05). Greater improvements were achieved in patients with elevated baseline blood eosinophil and/or FeNO levels for most outcomes.ConclusionsDupilumab improves lung function outcomes, including large and small airway measurements and fixed airway obstruction, in patients with uncontrolled, moderate-to-severe asthma; particularly in patients with elevated biomarkers of type 2 inflammation.

Sign in / Sign up

Export Citation Format

Share Document